BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10424999)

  • 1. Genetic evolutionary staging of early non-small cell lung cancer: the P53 --> HER-2/NEU --> ras sequence.
    Shackney SE; Smith CA; Pollice A; Levitt M; Magovern JA; Wiechmann RJ; Silverman J; Sweeney L; Landreneau RJ
    J Thorac Cardiovasc Surg; 1999 Aug; 118(2):259-67. PubMed ID: 10424999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
    Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
    Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common patterns of genetic evolution in human solid tumors.
    Shackney SE; Shankey TV
    Cytometry; 1997 Sep; 29(1):1-27. PubMed ID: 9298807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
    Shackney SE; Pollice AA; Smith CA; Janocko LE; Sweeney L; Brown KA; Singh SG; Gu L; Yakulis R; Lucke JF
    Clin Cancer Res; 1998 Apr; 4(4):913-28. PubMed ID: 9563885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 and HER-2/neu overexpression in ovarian borderline tumors.
    Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR
    Gynecol Oncol; 1997 May; 65(2):218-24. PubMed ID: 9159328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of features of human lung cancer cell lines and their corresponding tumors.
    Wistuba II; Bryant D; Behrens C; Milchgrub S; Virmani AK; Ashfaq R; Minna JD; Gazdar AF
    Clin Cancer Res; 1999 May; 5(5):991-1000. PubMed ID: 10353731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
    Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
    Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stratification of the biologic aggressiveness of non-small cell lung cancer using DNA flow cytometry and immunohistochemistry for the retinoblastoma protein.
    Otsuka H; Funai S; Tanaka A; Hara S; Shiozaki H
    Lung Cancer; 2004 Sep; 45(3):307-16. PubMed ID: 15301871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
    Wang Y; Zhang XR; Fu J; Tan W; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer.
    Miyamoto H; Harada M; Isobe H; Akita HD; Haneda H; Yamaguchi E; Kuzumaki N; Kawakami Y
    Cancer Res; 1991 Dec; 51(23 Pt 1):6346-50. PubMed ID: 1657384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.
    Harpole DH; Marks JR; Richards WG; Herndon JE; Sugarbaker DJ
    Clin Cancer Res; 1995 Jun; 1(6):659-64. PubMed ID: 9816029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preferred genetic evolutionary sequences in human breast cancer: a case study.
    Shackney SE; Smith CA; Pollice AA; Janocko LE; Singh SG; Groft DW; Brown KA; Hartsock RJ
    Cytometry; 1995 Sep; 21(1):6-13. PubMed ID: 8529472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The accumulation of multiple genetic abnormalities in individual tumor cells in human breast cancers: clinical prognostic implications.
    Shackney SE; Pollice AA; Smith CA; Alston L; Singh SG; Janocko LE; Brown KA; Petruolo S; Groft DW; Yakulis R; Hartsock RJ
    Cancer J Sci Am; 1996; 2(2):106-13. PubMed ID: 9166508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
    Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
    Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871.
    Carbone DP; Mitsudomi T; Chiba I; Piantadosi S; Rusch V; Nowak JA; McIntire D; Slamon D; Gazdar A; Minna J
    Chest; 1994 Dec; 106(6 Suppl):377S-381S. PubMed ID: 7988268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.